On October 7, INSILICO fell 8.68% in regular trading, trading at 54.85 HKD/share, with turnover of 56.0542 million HKD. The decline occurred amid a broader pullback in AI pharmaceutical stocks, despite the company's recent strong pipeline progress.
INSILICO recently nominated ISM1354, a next-generation small-molecule GIPR antagonist, as a preclinical candidate for obesity and type 2 diabetes, marking its 10th PCC nomination in the first nine months of the year. The company's shares had risen over 8% on September 30 following this announcement, reaching 59.95 HKD at close. However, short-term volatility in the sector has since intensified, with peers including GENSCRIPT BIO and XTALPI also declining sharply in the current session.
The company operates an AI-driven drug discovery platform, Pharma.AI, which has generated multiple clinical and IND-stage assets. Its pipeline includes Rentosertib, currently in Phase III trials for idiopathic pulmonary fibrosis.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)